Free Somatostatin Receptor Fraction Predicts the Antiproliferative Effect of Octreotide in a Neuroendocrine Tumor Model: Implications for Dose Optimization
- 1 December 2013
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 73 (23), 6865-6873
- https://doi.org/10.1158/0008-5472.can-13-1199
Abstract
Somatostatin receptors (SSTR) are highly expressed in well-differentiated neuroendocrine tumors (NET). Octreotide, an SSTR agonist, has been used to suppress the production of vasoactive hormones and relieve symptoms of hormone hypersecretion with functional NETs. In a clinical trial, an empiric dose of octreotide treatment prolonged time to tumor progression in patients with small bowel neuroendocrine (carcinoid) tumors, irrespective of symptom status. However, there has yet to be a dose optimization study across the patient population, and methods are currently lacking to optimize dosing of octreotide therapy on an individual basis. Multiple factors such as total tumor burden, receptor expression levels, and nontarget organ metabolism/excretion may contribute to a variation in SSTR octreotide occupancy with a given dose among different patients. In this study, we report the development of an imaging method to measure surface SSTR expression and occupancy level using the PET radiotracer 68Ga-DOTATOC. In an animal model, SSTR occupancy by octreotide was assessed quantitatively with 68Ga-DOTATOC PET, with the finding that increased occupancy resulted in decreased tumor proliferation rate. The results suggested that quantitative SSTR imaging during octreotide therapy has the potential to determine the fractional receptor occupancy in NETs, thereby allowing octreotide dosing to be optimized readily in individual patients. Clinical trials validating this approach are warranted. Cancer Res; 73(23); 6865–73. ©2013 AACR.This publication has 27 references indexed in Scilit:
- 68Ga-DOTATOC Versus 68Ga-DOTATATE PET/CT in Functional Imaging of Neuroendocrine TumorsJournal of Nuclear Medicine, 2011
- Treatment with Octreotide Does Not Reduce Tumor Uptake of 68Ga-DOTATATE as Measured by PET/CT in Patients with Neuroendocrine TumorsJournal of Nuclear Medicine, 2011
- Evolving Diagnostic and Treatment Strategies for Pancreatic Neuroendocrine TumorsJournal of Hematology & Oncology, 2011
- Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning MeetingJournal of Clinical Oncology, 2011
- NANETS Treatment GuidelinesPancreas, 2010
- 111In-pentetreotide scintigraphy: procedure guidelines for tumour imagingEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- Highly Efficient In Vivo Agonist-Induced Internalization of sst2 Receptors in Somatostatin Target TissuesJournal of Nuclear Medicine, 2009
- Processing of Generator-Produced 68Ga for Medical ApplicationJournal of Nuclear Medicine, 2007
- Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data. GeneralizationsJournal of Cerebral Blood Flow & Metabolism, 1985
- Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake DataJournal of Cerebral Blood Flow & Metabolism, 1983